Streetbeat News

Products Services

META

Meta Platforms (META) is poised to benefit significantly from a potential TikTok ban, as it could capture a larger share of the social media market. However, this opportunity may come with increased costs.

Portfolio Pulse from

December 20, 2024 | 3:45 pm

NVO

Novo Nordisk A/S (NYSE:NVO) stock plummeted 18.9% to $82.25 after its weight loss drug CagriSema failed to meet expectations in a late-stage study.

Portfolio Pulse from

December 20, 2024 | 3:45 pm

TOL

Toll Brothers, Inc. (NYSE:TOL) announced a new luxury home community, Toll Brothers at George's Ranch, in Boerne, Texas. The community will feature one-acre home sites and is expected to open for sale in early 2025.

Portfolio Pulse from

December 20, 2024 | 3:45 pm

D

Dominion Energy is capitalizing on the AI-driven data center boom, focusing on debt reduction and infrastructure upgrades to ensure long-term growth. Despite past challenges, it offers a 5.0% dividend yield and expects 5-7% annual EPS growth through 2029. Risks include rising bond rates and regulatory challenges.

Portfolio Pulse from

December 20, 2024 | 3:45 pm

KROS

Levi & Korsinsky has initiated an investigation into Keros Therapeutics, Inc. for potential securities law violations. Keros recently halted dosing in certain treatment arms of its TROPOS trial due to safety concerns.

Portfolio Pulse from

December 20, 2024 | 3:45 pm

LLY

NVO

Novo Nordisk's stock (NVO) is dropping over 20% in pre-market trading due to disappointing trial results for its weight-loss shot CagriSema. The results showed less weight loss than expected, impacting investor confidence. Eli Lilly (LLY), a competitor in the GLP-1 drug market, is also mentioned.

Portfolio Pulse from

December 20, 2024 | 3:45 pm

RZLV

Rezolve Ai (NASDAQ: RZLV) has been recognized by MarketBeat as a 'Next Big Winner' in AI for 2025, highlighting its innovative technology and strategic partnerships in the retail AI space.

Portfolio Pulse from

December 20, 2024 | 3:45 pm

NVO

Novo Nordisk's shares fell after the REDEFINE-1 trial results for CagriSema were positive but did not meet expectations. The trial's flexible dosing protocol affected the efficacy results.

Portfolio Pulse from

December 20, 2024 | 3:30 pm

MRK

Merck (MRK) announced successful results from two phase III studies of its two-drug, once-daily HIV pill, doravirine/islatravir, for adults with HIV-1. The studies met their primary goals, indicating potential for a new treatment option.

Portfolio Pulse from

December 20, 2024 | 3:30 pm

AAAU

Spot gold prices reached a session high of $2,620 per ounce following the confirmation of a 74 reading in the University of Michigan Consumer Sentiment index for December.

Portfolio Pulse from

December 20, 2024 | 3:30 pm